膀胱癌剂量递增自适应放疗:2期RAIDER随机对照试验结果
RAIDER是一项国际2期非比较随机对照试验,纳入345例单灶T2-T4a尿路上皮膀胱癌患者,按1:1:2随机接受标准全膀胱放疗、标准剂量自适应放疗或剂量递增自适应放疗。剂量递增自适应放疗组放疗相关晚期≥3级毒性低,达到预设安全性阈值,2年总生存率与标准放疗组相似(80% vs 77%,HR=0.84,95%CI 0.59-1.21,p=0.4)。
要点
- 剂量递增自适应放疗组≥3级晚期放疗毒性低,20f组1/58例,32f组0/56例。
- 剂量递增自适应放疗组与标准放疗组2年总生存率分别为80%和77%,HR=0.84,无显著差异。
- 全组345例中仅13例(3.8%)接受挽救性膀胱切除术。
核心结论
- 剂量递增自适应放疗的晚期≥3级毒性低,安全可行,达到预设毒性阈值。
- 剂量递增治疗的疾病相关结局有前景,挽救性膀胱切除率低,总生存与膀胱切除队列相似。
研究设计与样本
- 国际2期非比较随机对照试验(ISRCTN26779187),2015年10月至2020年4月共随机345例单灶T2-T4a尿路上皮膀胱癌患者。
- 按1:1:2随机分为标准全膀胱放疗组、标准剂量自适应放疗组和剂量递增自适应放疗组,两种分割方案独立招募。
- 标准全膀胱放疗和标准剂量自适应放疗剂量为55 Gy/20次或64 Gy/32次,剂量递增自适应放疗剂量为60 Gy/20次或70 Gy/32次。
- 标准剂量自适应放疗和剂量递增自适应放疗每日选择小、中或大计划。
主要发现
- 20次分割队列中,标准全膀胱放疗41/46例、标准剂量自适应放疗41/46例、剂量递增自适应放疗81/90例;32次分割队列中相应为41/46例、41/46例、81/90例。
- 中位年龄20次/32次队列分别为72岁和73岁;T2期分别占78%和85%;接受新辅助化疗分别占46%和52%;接受放疗增敏治疗分别占70%和71%。
- 中位随访时间分别为42.1个月和38.2个月。
- 剂量递增自适应放疗计划中,20次分割队列77例中66例(86%)、32次分割队列82例中74例(90%)满足强制中等计划剂量约束。
- 放疗相关≥3级毒性在20次分割剂量递增自适应放疗组为1/58例(90%CI 0.1-7.9),在32次分割剂量递增自适应放疗组为0/56例。
关键数值与推荐
- 主要终点为放疗相关晚期常见不良事件评价标准(CTCAE)≥3级毒性比例,试验设计旨在排除剂量递增自适应放疗毒性>20%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Delivering radiotherapy to the bladder is challenging as it is a mobile, deformable structure. Dose-escalated adaptive image-guided radiotherapy could improve outcomes. RAIDER aimed to demonstrate the safety of such a schedule. METHODS: RAIDER is an international phase 2 noncomparative randomised controlled trial (ISRCTN26779187). Patients with unifocal T2-T4a urothelial bladder cancer were randomised (1:1:2) to standard whole bladder radiotherapy (WBRT), standard-dose adaptive radiotherapy (SART), or dose-escalated adaptive radiotherapy (DART). Two fractionation (f) schedules recruited independently. WBRT and SART dose was 55 Gy/20f or 64 Gy/32f, and DART dose was 60 Gy/20f or 70 Gy/32f. For SART and DART, a radiotherapy plan (small, medium, or large) was chosen daily. The primary endpoint was the proportion of patients with radiotherapy-related late Common Terminology Criteria for Adverse Events grade ≥3 toxicity; the trial was designed to rule out >20% toxicity with DART. KEY FINDINGS AND LIMITATIONS: A total of 345 patients were randomised between October 2015 and April 2020: 41/46 WBRT, 41/46 SART, and 81/90 DART patients in the 20f/32f cohorts, respectively. The median age was 72/73 yr; 78%/85% had T2 tumours, 46%/52% had neoadjuvant chemotherapy, and 70%/71% had radiosensitising therapy. The median follow-up was 42.1/38.2 mo. Sixty-six of 77 (86%) 20f and 74 of 82 (90%) 32f participants planned for DART met the mandatory medium plan dose constraints. Radiotherapy-related grade ≥3 toxicity was reported in one of 58 patients (90% confidence interval [CI] 0.1, 7.9) with 20f DART and zero of 56 patients with 32f DART. Two-year overall survival was 77% (95% CI 69, 82) for WBRT + SART and 80% (95% CI 73, 85) for DART (hazard ratio = 0.84, 95% CI 0.59, 1.21, p = 0.4). Thirteen of 345 (3.8%) participants had salvage cystectomy. CONCLUSIONS AND CLINICAL IMPLICATIONS: Grade ≥3 late toxicity was low. DART was safe and feasible to deliver, meeting preset toxicity thresholds. Disease-related outcomes are promising for dose-escalated treatments, with a low salvage cystectomy rate and overall survival similar to that seen in cystectomy cohorts.
引用
- Huddart R, Hafeez S, Griffin C, et al. Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial. Eur Urol. 2024. PMID: 39379236. doi:10.1016/j.eururo.2024.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。